These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10528131)

  • 1. Cardiac effects of hexarelin in hypopituitary adults.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Aimaretti G; Pelosi E; Del Rio G; Muccioli G; Ong H; Boghen MF; Deghenghi R; Ghigo E
    Eur J Pharmacol; 1999 Sep; 381(1):31-8. PubMed ID: 10528131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Del Rio G; Arvat E; Boghen MF; Deghenghi R; Muccioli G; Ong H; Ghigo E
    J Endocrinol Invest; 1999 Apr; 22(4):266-72. PubMed ID: 10342360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.
    Imazio M; Bobbio M; Broglio F; Benso A; Podio V; Valetto MR; Bisi G; Ghigo E; Trevi GP
    Eur J Heart Fail; 2002 Mar; 4(2):185-91. PubMed ID: 11959048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired cardiac performance in elderly patients with growth hormone deficiency.
    Colao A; Cuocolo A; Di Somma C; Cerbone G; Della Morte AM; Nicolai E; Lucci R; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3950-5. PubMed ID: 10566633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery.
    Broglio F; Guarracino F; Benso A; Gottero C; Prodam F; Granata R; Avogadri E; Muccioli G; Deghenghi R; Ghigo E
    Eur J Pharmacol; 2002 Jul; 448(2-3):193-200. PubMed ID: 12144941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy.
    Broglio F; Benso A; Valetto MR; Gottero C; Quaranta L; Podio V; Arvat E; Bobbio M; Bisi G; Ghigo E
    Endocrine; 2001 Feb; 14(1):105-8. PubMed ID: 11322491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
    Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.
    Gasperi M; Aimaretti G; Scarcello G; Corneli G; Cosci C; Arvat E; Martino E; Ghigo E
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2633-7. PubMed ID: 10443652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.
    Aimaretti G; Baffoni C; Bellone S; Di Vito L; Corneli G; Arvat E; Benso L; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3693-9. PubMed ID: 11061526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment.
    Valcavi R; Gaddi O; Zini M; Iavicoli M; Mellino U; Portioli I
    J Clin Endocrinol Metab; 1995 Feb; 80(2):659-66. PubMed ID: 7852533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone-independent cardioprotective effects of hexarelin in the rat.
    Locatelli V; Rossoni G; Schweiger F; Torsello A; De Gennaro Colonna V; Bernareggi M; Deghenghi R; Müller EE; Berti F
    Endocrinology; 1999 Sep; 140(9):4024-31. PubMed ID: 10465272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.
    Popovic V; Pekic S; Golubicic I; Doknic M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 2002 May; 87(5):2095-9. PubMed ID: 11994347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.
    Aimaretti G; Corneli G; Razzore P; Bellone S; Baffoni C; Arvat E; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1998 May; 83(5):1615-8. PubMed ID: 9589665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of growth hormone (GH) therapy on cardiac performance in patients with childhood onset GH deficiency.
    Minczykowski A; Gryczynska M; Ziemnicka K; Czepczynski R; Sowinski J; Wysocki H
    Growth Horm IGF Res; 2005 Apr; 15(2):156-64. PubMed ID: 15809020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone status during long-term hexarelin therapy.
    Rahim A; O'Neill PA; Shalet SM
    J Clin Endocrinol Metab; 1998 May; 83(5):1644-9. PubMed ID: 9589671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.
    Rossoni G; Locatelli V; Gennaro Colonna Vd ; Müller EE; Berti F
    Pharmacol Res; 2000 Aug; 42(2):129-36. PubMed ID: 10887041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; DEl Rio G; Boghen MF; Berti F; Muller EE; Ghigo E
    Eur J Endocrinol; 1999 Apr; 140(4):322-7. PubMed ID: 10097251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.